Σφακιανάκης Αλέξανδρος
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5 Άγιος Νικόλαος
Κρήτη 72100
00302841026182
00306932607174
alsfakia@gmail.com

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Πέμπτη 6 Απριλίου 2017

Effect of combined hormonal replacement therapy on the aldosterone/renin ratio in postmenopausal women.

Effect of combined hormonal replacement therapy on the aldosterone/renin ratio in postmenopausal women.

J Clin Endocrinol Metab. 2017 Mar 30;:

Authors: Ahmed AH, Gordon RD, Ward G, Wolley M, McWhinney BC, Ungerer JP, Stowasser M

Abstract
Background: Plasma aldosterone/renin ratio (ARR) is the most popular screening test for primary aldosteronism (PA). Because both estrogen and progesterone (including in oral contraceptive agents) affect aldosterone and renin levels, we studied effects of combined hormonal replacement therapy (HRT) on ARR, measuring renin as both direct renin concentration (DRC) and plasma renin activity (PRA).
Methods: Fifteen normotensive, healthy postmenopausal women underwent measurement (seated, midmorning) of plasma aldosterone, DRC, PRA, electrolytes and creatinine and urinary aldosterone, cortisol, electrolytes and creatinine at baseline and after 2 weeks and 6 weeks treatment with combined HRT (conjugated oestrogens 0.625 mg and medroxyprogesterone 2.5 mg daily).
Results: Treatment with combined HRT was associated with significant increases in aldosterone [baseline median (range) 150 (85-600), 2 weeks 230 (129-790), 6 weeks 434 (200-1200) pmol/L; P<0.001 (Friedman Test)] and PRA [2.3 (1.2-4.3), 3.8 (1.4-7.0), 5.1 (1.4-10.8) ng/mL/h; P<0.001]; but decreases in DRC [21 (10-31), 21 (10-39), 14 (8.0-30) mU/L; P<0.01] leading to increases in ARR calculated by DRC [7.8 (3.6-34.8), 11.4 (5.4-48.5), 30.4 (10.5-90.2); P<0.001]. The ARR calculated by DRC exceeded the cut off value (70) in three patients after 6 weeks. There were no significant changes in ARR calculated by PRA [79 (26-184), 91 (23-166), 88 (50-230); P=0.282], plasma electrolytes and creatinine, and all urinary measurements.
Conclusion: The combined oral HRT used in this study is capable of significantly increasing ARR with a risk of false positive results during screening for PA, but only if DRC (and not PRA) is used to calculate the ratio.

PMID: 28379474 [PubMed - as supplied by publisher]



http://ift.tt/2p4khFA

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου